...
首页> 外文期刊>Journal of Medicinal Chemistry >Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety.
【24h】

Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety.

机译:15-脱氧精豆素新类似物的结构-免疫抑制活性关系。 2.亚精胺部分的结构修饰。

获取原文
获取原文并翻译 | 示例

摘要

A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. Various substitutions of the spermidine "D" region were made in order to determine its optimum structure in terms of in vivo immunosuppressive activity. Various positions of methylation were first investigated leading to the discovery of the monomethylated malonic derivative 56h in which the pro-R hydrogen of the methylene alpha to the primary amine of the spermidine moiety has been replaced by a methyl group. Synthesis of the similarly methylated analogue of the previously reported glycolic derivative LF 08-0299 afforded 60e which demonstrated a powerful activity at a dose as low as 0.3 mg/kg in the GVHD model and was much more potent than DSG in the demanding heart allotransplantation model in rats. The improvement of in vivo activity was supposed to be related to an increase of the metabolic stability of the methylated analogues compared to the parent molecules. Due to its very low active dose, compatible with a subcutaneous administration in humans, and its favorable pharmacological and toxicological profile, 60e was selected as a candidate for clinical evaluation.
机译:合成了一系列在日本商业化的免疫抑制剂15-脱氧精油素(DSG)的新类似物,并在小鼠移植物抗宿主病(GVHD)模型中对其进行了测试。为了确定其在体内免疫抑制活性方面的最佳结构,对亚精胺“ D”区进行了各种取代。首先研究了甲基化的各种位置,从而发现了单甲基化的丙二酸衍生物56h,其中亚甲基α到亚精胺部分的伯胺的pro-R氢已被甲基取代。先前报道的乙醇衍生物LF 08-0299的类似甲基化类似物的合成提供了60e,该化合物在GVHD模型中的剂量低至0.3 mg / kg时显示出强大的活性,并且在要求严格的心脏同种异体移植模型中比DSG更有力在大鼠中。与母体分子相比,体内活性的改善被认为与甲基化类似物的代谢稳定性的增加有关。由于60e具有非常低的活性剂量,与人类皮下给药兼容,并且具有良好的药理和毒理特性,因此选择60e作为临床评估的候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号